----

----

|   | 1. | Section 4.5 of the Agreement shall be replaced with the following paragraph: |
|--------|----|------------------------------------------------------------------------------|

|   | 2. | Section 6.4(a) of the Agreement shall be replaced with the following paragraph: |
|--------|----|---------------------------------------------------------------------------------|

| [*****] Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission.Fourth Amendment to the Exclusive Manufacturing, Supply and Distribution Agreement |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Minimum Period(Calendar Year) | Minimum Purchase Levels(50 mL vials) |
|-------------------------------|--------------------------------------|
| 2010                          | [*****]                              |
| 2011                          | [*****]                              |
| 2012                          | [*****]                              |
| 2013                          | [*****]                              |
| 2014                          | [*****]                              |
| 2015                          | [*****]                              |
| 2016                          | [*****]                              |
| 2017                          | [*****]                              |
| 2018                          | [*****]                              |

|   | 3. | Section 1.77 of the Agreement is hereby amended to read as follows: |
|--------|----|---------------------------------------------------------------------|

| Calendar Year | 50 mL vials/month |
|---------------|-------------------|
| 2010          | [*****]           |
| 2011          | [*****]           |
| 2012          | [*****]           |
| 2013          | [*****]           |
| 2014          | [*****]           |
| 2015          | [*****]           |
| 2016          | [*****]           |
| 2017          | [*****]           |
| 2018          | [*****]           |

| [*****] Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission.Fourth Amendment to the Exclusive Manufacturing, Supply and Distribution Agreement | Page 2 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|

----

|   | 4. | A new section 5.4 (c) shall be added to the Agreement, as follows: |
|--------|----|--------------------------------------------------------------------|

| Amount        | Payment Date                                                                                                                                   |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| [*****]       | Thirty (30) days after reaching Net Sales for the Product and Baxalta’s Product of [*****] during the period of [*****] through [*****]. |
| [*****]  | Thirty (30) days after reaching Net Sales for the Product and Baxalta’s Product of [*****] during the period of [*****] through [*****]. |

|   | 5. | As Baxter Healthcare Corporation has assigned the Agreement to Baxalta, all references to Baxter in the Agreement shall now be read to refer to Baxalta. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6. | All provisions of the Agreement which are not expressly amended by the terms of this Third Amendment shall remain in effect and without change. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------|

| BAXALTA US INC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | KAMADA LTD.                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| By: /s/ Ludwig Hantson                                           Name: Ludwig HantsonTitle: CEO & PresidentDate: 10/15/15                                             | By: /s/ Amir London                                           Name:  Amir LondonTitle:  Chief Executive OfficerDate: August 25, 2015      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | By: /s/ Gil Efron                                           Name: Gil EfronTitle:  Deputy CEO and Chief Financial OfficerDate: August 25, 2015 |

| [*****] Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission.Fourth Amendment to the Exclusive Manufacturing, Supply and Distribution Agreement | Paeg 3 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|

----

----